TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05601076

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fixed with the triple-buffer system
Description: The steps were as follows: i) elastic cotton tape (3M 2733-25 Japan Ltd., Tokyo, Japan) was used at the proximal 15 cm from the incision, with 5 × 2.5 cm pieces glued to the skin and fixed with the drainage tube using surgical knots; ii) the distal end of the ligation was fixed using the same method, while the ligation position was higher than the first; iii) the ligature point was fixed next to the elastic soft cotton tape (5 × 5 cm), using the high-platform method to fix the drainage tube, with the drainage tube curved; and iv) the drainage tube between the two fixed points was inserted with a specific radian.
Study: NCT03956953

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching Dose 1 or Dose 2 on Day 1, and from Days 5-19
Study: NCT02145299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TruePath CTO Device
Description: The TruePath CTO Device is composed of a 0.018 guidewire and a motor housing with a connector cable along with a sterile, disposable battery-powered Control Unit for manipulation of the device during operation. The TruePath CTO Device is indicated to facilitate the intra-luminal placement of conventional guidewires beyond peripheral artery chronic total occlusions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CROSSER CTO Device
Study: NCT01762293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib
Description: Famitinib 25 mg p.o. qd

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: p.o. qd
Study: NCT02388061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tissue Plasminogen Activator
Study: NCT05601076

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fixed using the conventional lifting platform method
Description: In terms of the control group, two lines of flexible cotton tape (3M 2733-25 Japan Ltd., Tokyo, Japan) measuring 10 × 2.5 cm were used, and the drainage tube was fixed parallel to the long axis and glued to the middle-position 360° winding tube once the drainage tube was 0.5 cm higher than the surrounding skin. Next, the drainage tube was fixed at both ends to the patient's skin using adhesive tape. Then, the tube and the adhesive plaster were overlapped vertically and horizontally, the tube was inserted, the adhesive plaster was added, and then the chest tube was fixed on the adhesive plaster by knotting the interspersed cotton rope, which was equal to indirectly fixing the tube on the patient's skin
Study: NCT00531362

Intervention type: DRUG
Intervention: Plain aspirin
Description: Plain aspirin 75 mg or 150 mg
Study: NCT04105114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: Oral Buspirone 7.5mg - 10mg daily during the treatment phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: Oral Buspirone 7.5mg - 10mg daily during the treatment phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: Oral Buspirone 7.5mg - 10mg daily during the treatment phase.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive Spinal Cord Stimulation
Description: A non-invasive transcutaneous electrical spinal cord stimulator, which can be used a multiple spinal locations.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive Spinal Cord Stimulation
Description: A non-invasive transcutaneous electrical spinal cord stimulator, which can be used a multiple spinal locations.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive Spinal Cord Stimulation
Description: A non-invasive transcutaneous electrical spinal cord stimulator, which can be used a multiple spinal locations.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ekso Bionics Exoskeleton
Description: This robotic exoskeleton is designed to assist people with neurological injuries for balance, standing, and stepping overground.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ekso Bionics Exoskeleton
Description: This robotic exoskeleton is designed to assist people with neurological injuries for balance, standing, and stepping overground.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gravity Neutral Device
Description: This device is used to train and assess non-weight bearing stepping movements. When using the device, participants will be lying on their side with their legs suspended off the end of a table supported by small slings that are anchored securely to the apparatus.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Body Weight Supported Treadmill Training
Description: Participants will be supported by a special harness while they are stepping on a treadmill. Trained technicians or therapists will be assist the trunk and legs during stepping as needed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rolling Walker
Description: A standard rolling walker will be used for balance support and stability during stepping overground.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rolling Walker
Description: A standard rolling walker will be used for balance support and stability during stepping overground.
Study: NCT02656251

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.12% Clorhexidine with alcohol
Description: Use of 0.12% Clorhexidine with alcohol every 12 hours for 04 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.12% Clorhexidine with alcohol
Description: Use of 0.12% Clorhexidine with alcohol every 12 hours for 04 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.12% Clorhexidine with alcohol
Description: Use of 0.12% Clorhexidine with alcohol every 12 hours for 04 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Use of placebo every 12 hours for 04 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Use of placebo every 12 hours for 04 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Use of placebo every 12 hours for 04 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.12% Clorhexidine without alcohol
Description: Use of 0.12% Clorhexidine without alcohol, every 12 hours for 04 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.12% Clorhexidine without alcohol
Description: Use of 0.12% Clorhexidine without alcohol, every 12 hours for 04 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.12% Clorhexidine without alcohol
Description: Use of 0.12% Clorhexidine without alcohol, every 12 hours for 04 days
Study: NCT03381196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimodivir 600 mg
Description: Participants will receive pimodivir 600 mg, orally, twice daily, for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 \[evening\], dosing will continue until the morning of Day 6).
Study: NCT01884454

Intervention type: BEHAVIORAL
Intervention: Sleep deprivation
Description: Volunteers will be submitted to total sleep deprivation (SD) or selective REM sleep deprivation for 48 hours. After SD, these volunteers will be allowed to sleep for 48 hours (period rebound).

Intervention type: BEHAVIORAL
Intervention: Sleep deprivation
Description: Volunteers will be submitted to total sleep deprivation (SD) or selective REM sleep deprivation for 48 hours. After SD, these volunteers will be allowed to sleep for 48 hours (period rebound).
Study: NCT01952145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/liraglutide
Description: Insulin degludec/liraglutide is injected subcutaneously s.c. (under the skin) once daily (OD). Dose individually adjusted. Subjects should continue their pre-trial treatment with metformin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Insulin glargine is injected subcutaneously s.c. (under the skin) once daily (OD). Dose individually adjusted. Subjects should continue their pre-trial treatment with metformin.
Study: NCT02752035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gilteritinib
Description: Tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gilteritinib
Description: Tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gilteritinib
Description: Tablet, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Subcutaneous injection or intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: azacitidine
Description: Subcutaneous injection or intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Subcutaneous injection or intravenous infusion
Study: NCT04344795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPST-1495 twice daily
Description: TPST-1495 administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPST-1495 once daily or on intermittent schedule
Description: TPST-1495 administered orally once daily or on intermittent schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPST-1495 once daily or on intermittent schedule
Description: TPST-1495 administered orally once daily or on intermittent schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPST-1495 once daily or on intermittent schedule
Description: TPST-1495 administered orally once daily or on intermittent schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPST-1495 once daily or on intermittent schedule
Description: TPST-1495 administered orally once daily or on intermittent schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab dosed per label recommendations

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab dosed per label recommendations
Study: NCT06638476

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perturbation Induced Step training
Description: A sudden lateral displacement of the treadmill.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Voluntary step training
Description: Voluntary steps emphasizing speed, movement of center of mass and taking larger steps.
Study: NCT03359772

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesthetic Ability Trainer
Description: Kinesthetic Ability Trainer
Study: NCT02026167

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Collaborative Care
Description: Addition of a Health Care Assistant to treatment team, case review by expert panel of supervisors, non-medical interventions
Study: NCT01462747

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: KULIST
Description: Twice daily dosing for 8 weeks
Study: NCT02304159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daclatasvir
Study: NCT00178633

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Bariatric surgery was not part of this trial. This was observational trial of persons post-bariatric surger.
Study: NCT00310167

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study: NCT02304159

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: daclatasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir, Sovaldi

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir, Sovaldi

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Study: NCT04466839

Intervention type: OTHER
Intervention: Questionnaire and interview
Description: The questionnaires are Parkinson Disease Questionnaire-8 Items (PDQ-8) Visual Analog Scale (VAS) is visual analog scale visual numeric from 0 to 100, Neuropsychiatric Inventory-Questionnaire-Reduced (NPI-R) and Clinical Global Impression-Impairment (CGI-I).
Study: NCT01370044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbogen
Description: 3 minutes administration of carbogen

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 minutes administration of oxygen
Study: NCT01405664

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight-Bearing as Tolerated
Description: WBAT immediately after surgery
Study: NCT06061185

Intervention type: DEVICE
Intervention: Multimodal CT
Description: Non-contrast computed tomography, computed tomography angiography and computed tomography perfusion
Study: NCT03572283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bethanechol
Description: Supplied as 50mg oral tablets. Take 2 tablets (total 100mg) twice daily from day 1 for a minimum of 1 week and a maximum of 4 weeks (or 2 days prior to scheduled surgery). Medication should be taken 1 hour before meals in the morning and the evening. Although bethanechol is FDA approved, in this study its use is experimental.
Study: NCT00023595

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG surgery plus MED
Description: CABG plus standard medication management for Coronary Artery Disease

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG surgery plus MED
Description: CABG plus standard medication management for Coronary Artery Disease
Study: NCT01864759

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ICOVIR-5
Study: NCT00023595

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Medication Alone
Description: Standard medication for coronary artery disease and heart failure management.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG plus MED and SVR
Description: H02: the experimental arm receives active medical therapy and CABG and surgical ventricular restoration whereas the control group receives active medical therapy and CABG; for H01: the experimental arm receives active medical therapy and CABG whereas the control group receives active medical therapy alone
Study: NCT03257072

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 50 Necator americanus L3 larvae
Description: 1x50 Necator americanus L3 larvae

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 100 Necator americanus L3 larvae
Description: 2x50 Necator americanus L3 larvae
Study: NCT01504360

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: tumor genetic predisposition to develop sarcoma assessment
Description: data concerning initial radiation and localisation of the sarcoma secondary developed will be collected. 2 blood samples (2 x 5 ml)will be collected. One sample of 5 mm will be dedicated to study radiation induced apoptosis assessed by flow cytometry. The second sample will be used to study the polymorphism of the genes involved in reparation of DNA by using chip screening of single nucleotide polymorphisms (SNP). DNA will be extracted and controlled by flow cytometrical separation.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: tumor genetic predisposition to develop sarcoma assessment
Description: data concerning initial radiation and data demonstrating the lack of secondary sarcoma will be collected . 2 blood samples (2 x 5 ml)will be collected. One sample of 5 mm will be dedicated to study radiation induced apoptosis assessed by flow cytometry. The second sample will be used to study the polymorphism of the genes involved in reparation of DNA by using chip screening of single nucleotide polymorphisms (SNP). DNA will be extracted and controlled by flow cytometrical separation.
Study: NCT04611243

Intervention type: BIOLOGICAL
Intervention: third dose vaccination with CoronaVac vaccine
Description: Healthy individuals with low antibody levels after 2 doses of CoronaVac vaccine to receive one additional dose of CoronaVac vaccine

Intervention type: BIOLOGICAL
Intervention: third dose vaccination with BionTech vaccine
Description: Healthy individuals with low antibody levels after 2 doses of CoronaVac vaccine to receive one additional dose of BionTech vaccine

Intervention type: BIOLOGICAL
Intervention: Vaccination with Coronavac vaccine
Description: Healthy individuals to receive Coronavac vaccine 2 doses, 21 days apart

Intervention type: BIOLOGICAL
Intervention: Vaccination with BionTech Vaccine
Description: Healthy individuals to receive BionTech vaccine 2 doses, 21 days apart
Study: NCT03490240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BIPAMS
Description: The primary content of the website is delivered through interactive video courses. The interactive video courses are released seven times during the first two months, four times during the second two months, and twice during the final two months of the intervention.~Another key part of the website is the Tracker feature. This feature allows for tracking of daily step counts (via Yamax SW-200 pedometer) as well as setting goals and monitoring progress over the program.~The one-on-one video chats are conducted face to face through skype and are semi-scripted. The chats consist of an ongoing review of goal-setting and progress toward goal attainment through Tracker as well as discussion of strategies and facilitators of behavioral change based on SCT and current website content. The chats occur seven times during the first two months, four times during the second two months, and twice during the final two months of the intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WELLMS
Description: The control condition focuses on self-managing MS through means other than physical activity. The materials are transformations of brochures provided by the NMSS, including Gait or Walking Problems: The Basic Facts; MS and Your Emotions; Pain: The Basic Facts; Solving Cognitive Problems; Taming Stress in MS; Food for Thought: MS and Nutrition; and Vitamins, Minerals, and Herbs: An Introduction. The delivery of the Internet materials and chat sessions will occur on the same time schedule and frequency as the intervention condition, and will have a comparable time commitment. The control condition will account for attention and social contact as well as other possible biases such as initial reactivity and time spent on the website and video chats. The participants in the control condition will not be offered the behavioral intervention for increasing physical activity after completion of the study procedures.
Study: NCT02891356

Intervention type: DEVICE
Intervention: DEXA
Description: The Dual Energy X-ray Absorptiometry (DEXA) is a third generation multi-captor DEXA device that allow short duration measurements. It measures Bone Mineral Density (BMD) at the spine and the femoral neck
Study: NCT05651490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Solving Treatment for Diabetes
Description: In the introductory session, the structure of and rationale behind PST-D will be explained. The specialist will work with the participant to develop a problem list related to diabetes self-management and smoking cessation, if applicable.~During the weekly sessions, the participant will be taught and guided through the seven steps of problem solving:~1. Clarifying and defining the problem~2. Setting a realistic goal~3. Brainstorming multiple solutions~4. Generating pros and cons for each solution~5. Evaluating and choosing a preferred solution~6. Developing a specific action plan to implement the solution~7. Evaluating outcomes from the previous session.~Participants will also plan to engage in at least 1 enjoyable activity daily during the week.~The number of sessions will differ based on the specialist's assessment of the participant's problem-solving skills.~Maintenance sessions will be delivered monthly across 3 months in order to follow-up with participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Group
Description: During the sessions, the healthcare practitioners will provide general information and recommendations on general health topics such as oral health, hearing loss, sleep, dementia, adult vaccination, influenza, and dengue fever. Participants will also be given handouts adapted from government agencies and/or public bodies, such as HealthHub, National Health Service, National Addictions Management Service, and National Environmental Agency, on these topics. The healthcare practitioners will avoid discussing topics related to diabetes, diet, physical activity, and medication.
Study: NCT03070665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Increasing blood pressure up to 150mmHg for 5min using norepinephrine pump as initial dose 0.05μg/Kg.min during ESD operation, meanwhile check out the potential hemorrhage spot which is not obvious and then use the hot biopsy forceps to coagulate the bleeding spot, after that withdraw the norepinephrine and record the potential bleeding spot's location. The other procedures are the same as control groups'.
Study: NCT01379690

Intervention type: OTHER
Intervention: HBA1C
Description: Used level of HBA1C as a reflection of glycaemic control of the cases and controls

Intervention type: OTHER
Intervention: HBA1C
Description: Used level of HBA1C as a reflection of glycaemic control of the cases and controls
Study: NCT04417530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AU-011
Description: AU-011 Via Suprachoroidal Administration with laser treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AU-011
Description: AU-011 Via Suprachoroidal Administration with laser treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AU-011
Description: AU-011 Via Suprachoroidal Administration with laser treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AU-011
Description: AU-011 Via Suprachoroidal Administration with laser treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AU-011
Description: AU-011 Via Suprachoroidal Administration with laser treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AU-011
Description: AU-011 Via Suprachoroidal Administration with laser treatment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suprachoroidal Microinjector
Description: Suprachoroidal Injection Device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suprachoroidal Microinjector
Description: Suprachoroidal Injection Device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suprachoroidal Microinjector
Description: Suprachoroidal Injection Device
Study: NCT00310167

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT03257072

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 150 Necator americanus L3 larvae
Description: 3x50 Necator americanus L3 larvae
Study: NCT00944606

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 2000-3000 IU Vitamin D daily x 6 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo candy
Description: candy gum drops
Study: NCT02318914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gevokizumab